Recent Finacing
Recent Raise
Fusion Pharmaceuticals is a clinical‑stage biopharma developing targeted alpha‑particle radiotherapeutics using a Fast‑Clear™ linker to deliver actinium‑225 via antibodies and engineered proteins, advancing FPI‑1434 in clinical trials.
